Wenqing Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenqing Jia has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Yong-Zhi Wang
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
12 shared publications Jun Yang
Beijing Neurosurgical Institute
9 shared publicationsBo Wang
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
8 shared publicationsWei-Hao Liu
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
7 shared publicationsYao-Wu Zhang
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
7 shared publicationsChong Wang
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
6 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 23 (4) , 766-776
The Final-to-Baseline Amplitude Reduction Ratio of Intraoperative Motor Evoked Potentials Predicts Early Neurological Deficits Following Intradural Extramedullary Tumor Resection
Objective: To evaluate the predictive value of the final-to-baseline amplitude reduction ratio (FBR) of motor evoked potentials (MEP) and somatosensory evoked potentials (SEP) for early postoperative neurological deficits (PNDs) following intradural extramedullary (IDEM) tumor resection, and to explore a candidate prognostic cutoff for intraoperative neurophysiological monitoring (IONM).Methods: A total of 123 consecutive patients who underwent IDEM tumor resection with multimodal IONM were retrospectively analyzed. Early PND was defined as ≥1-grade increase in the modified McCormick scale at 1 month postoperatively. MEP and SEP FBRs were calculated and analyzed using multivariable logistic regression and receiver operating characteristic (ROC) curve analysis.Results: Early PND occurred in 26.02% (32 of 123) of patients. Multivariable regression identified MEP FBR as the sole independent predictor of early PND (odds ratio, 1.064; 95% confidence interval, 1.040–1.088; p<0.001). ROC analysis demonstrated excellent predictive performance with an area under the curve of 0.922 (p<0.001) and an optimal cutoff value of 61.84%. MEP FBR showed a significant graded association with PND severity (p<0.001).Conclusion: Our findings suggest MEP FBR may serve as a promising predictor of early postoperative neurological deficit among patients undergoing IDEM tumor resection. A multimodal IONM strategy centered on MEP monitoring, with SEP as a supplement appears reasonable for IDEM tumor resection. A 60% reduction in MEP amplitude may represent an exploratory prognostic cutoff warranting prospective validation.
- 31 October 2026
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 23 (4) , 766-776
Open AccessThe Final-to-Baseline Amplitude Reduction Ratio of Intraoperative Motor Evoked Potentials Predicts Early Neurological Deficits Following Intradural Extramedullary Tumor Resection
Objective: To evaluate the predictive value of the final-to-baseline amplitude reduction ratio (FBR) of motor evoked potentials (MEP) and somatosensory evoked potentials (SEP) for early postoperative neurological deficits (PNDs) following intradural extramedullary (IDEM) tumor resection, and to explore a candidate prognostic cutoff for intraoperative neurophysiological monitoring (IONM).Methods: A total of 123 consecutive patients who underwent IDEM tumor resection with multimodal IONM were retrospectively analyzed. Early PND was defined as ≥1-grade increase in the modified McCormick scale at 1 month postoperatively. MEP and SEP FBRs were calculated and analyzed using multivariable logistic regression and receiver operating characteristic (ROC) curve analysis.Results: Early PND occurred in 26.02% (32 of 123) of patients. Multivariable regression identified MEP FBR as the sole independent predictor of early PND (odds ratio, 1.064; 95% confidence interval, 1.040–1.088; p<0.001). ROC analysis demonstrated excellent predictive performance with an area under the curve of 0.922 (p<0.001) and an optimal cutoff value of 61.84%. MEP FBR showed a significant graded association with PND severity (p<0.001).Conclusion: Our findings suggest MEP FBR may serve as a promising predictor of early postoperative neurological deficit among patients undergoing IDEM tumor resection. A multimodal IONM strategy centered on MEP monitoring, with SEP as a supplement appears reasonable for IDEM tumor resection. A 60% reduction in MEP amplitude may represent an exploratory prognostic cutoff warranting prospective validation.
- 18 May 2026
- Published by Springer Nature in European Spine Journal
- p. 1-11
Preoperative risk stratification for long-term neurological status in spinal ependymoma: an MRI-centered nomogram
Purpose Despite favorable long-term survival in WHO grade 2 spinal ependymoma, long-term neurological impairment remains clinically important. This study aimed to develop an MRI-centered preoperative nomogram for individualized prediction of long-term unfavorable neurological status. Methods This retrospective study included 582 patients with histopathologically confirmed WHO grade 2 spinal ependymoma. Long-term neurological status was assessed using the modified McCormick Scale (MMS), with final MMS > II defined as unfavorable status. Candidate preoperative predictors were evaluated using univariable logistic regression and collinearity diagnostics. The final model incorporated preoperative MMS and five routinely available MRI predictors: tumor-to-cord ratio, tumor location, intratumoral hemorrhage, peripheral edema, and MRI classification. Model performance was assessed using discrimination, calibration, bootstrap internal validation, and decision curve analysis. Results Among 582 patients, 120 had unfavorable neurological status at final follow-up. The final MRI-centered model showed good discrimination, with an apparent AUC of 0.818 (95% CI, 0.776–0.859) and an optimism-corrected AUC of 0.797 after 1000 bootstrap resamples. Calibration analysis showed satisfactory agreement between predicted and observed probabilities, with a Brier score of 0.125. Decision curve analysis demonstrated positive net benefit over an approximate threshold range of 0.01–0.66. Conclusion An MRI-centered preoperative nomogram integrating preoperative MMS and routinely available MRI predictors may support individualized risk stratification in patients with WHO grade 2 spinal ependymoma. This tool may assist preoperative counseling and risk-informed surgical planning, although external validation is required before broader clinical implementation.
- 18 May 2026
- Published by Springer Nature in European Spine Journal
- p. 1-11
Preoperative risk stratification for long-term neurological status in spinal ependymoma: an MRI-centered nomogram
Purpose Despite favorable long-term survival in WHO grade 2 spinal ependymoma, long-term neurological impairment remains clinically important. This study aimed to develop an MRI-centered preoperative nomogram for individualized prediction of long-term unfavorable neurological status. Methods This retrospective study included 582 patients with histopathologically confirmed WHO grade 2 spinal ependymoma. Long-term neurological status was assessed using the modified McCormick Scale (MMS), with final MMS > II defined as unfavorable status. Candidate preoperative predictors were evaluated using univariable logistic regression and collinearity diagnostics. The final model incorporated preoperative MMS and five routinely available MRI predictors: tumor-to-cord ratio, tumor location, intratumoral hemorrhage, peripheral edema, and MRI classification. Model performance was assessed using discrimination, calibration, bootstrap internal validation, and decision curve analysis. Results Among 582 patients, 120 had unfavorable neurological status at final follow-up. The final MRI-centered model showed good discrimination, with an apparent AUC of 0.818 (95% CI, 0.776–0.859) and an optimism-corrected AUC of 0.797 after 1000 bootstrap resamples. Calibration analysis showed satisfactory agreement between predicted and observed probabilities, with a Brier score of 0.125. Decision curve analysis demonstrated positive net benefit over an approximate threshold range of 0.01–0.66. Conclusion An MRI-centered preoperative nomogram integrating preoperative MMS and routinely available MRI predictors may support individualized risk stratification in patients with WHO grade 2 spinal ependymoma. This tool may assist preoperative counseling and risk-informed surgical planning, although external validation is required before broader clinical implementation.
- Open Access
- 11 May 2026
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (8) , 3961-3969
Intraoperative Bulbocavernosus Reflex Monitoring for Predicting Bowel Function After Resection of Conus Medullaris and Cauda Equina Tumors
Study Design: Retrospective cohort study. Objective: To evaluate the predictive value of intraoperative bulbocavernosus reflex (BCR) monitoring for postoperative bowel dysfunction (PBD) following conus medullaris and cauda equina tumor (CMCET) resection. Methods: A total of 118 patients were analyzed. Neurogenic Bowel Dysfunction Scores >6 at 1 month and 6 months postoperatively defined short- and long-term PBD. The amplitude reduction ratio (ARR) was calculated from bilateral BCR waveforms using the worst-side ARR for analysis. Multivariate logistic regression and ROC curve analysis determined independent predictors and optimal thresholds. Stratified 10-fold cross-validation confirmed threshold stability. Results: Patients with short-term or long-term PBD had significantly higher ARRs than those without ( P < 0.001 for both comparisons, Mann-Whitney U test). Furthermore, ARR emerged as the only independent predictor for either short-term (OR 1.287, 95% CI 1.018-1.627, P = 0.035) or long-term PBD (OR 1.153, 95% CI 1.055-1.261, P = 0.002). The threshold values of ARR for predicting short-term and long-term PBD were 59.6% (AUC = 0.991, 95% CI 0.974-1.000, P < 0.001) and 63.6% (AUC = 0.988, 95% CI 0.971-1.000, P < 0.001), respectively. Cross-validation confirmed these thresholds, with mean AUC values of 0.992 and 0.993 for short-term and long-term PBD, respectively. Conclusions: The ARR of the intraoperative BCR waveform showed a high predictive value for PBD in patients with CMCET. We propose a 60% ARR reduction on either side of the BCR waveforms as an exploratory, hypothesis-generating early warning criterion for BCR monitoring during CMCET surgery, pending external validation in independent prospective cohorts before clinical implementation.
- 11 May 2026
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (8) , 3961-3969
Open AccessIntraoperative Bulbocavernosus Reflex Monitoring for Predicting Bowel Function After Resection of Conus Medullaris and Cauda Equina Tumors
Study Design: Retrospective cohort study. Objective: To evaluate the predictive value of intraoperative bulbocavernosus reflex (BCR) monitoring for postoperative bowel dysfunction (PBD) following conus medullaris and cauda equina tumor (CMCET) resection. Methods: A total of 118 patients were analyzed. Neurogenic Bowel Dysfunction Scores >6 at 1 month and 6 months postoperatively defined short- and long-term PBD. The amplitude reduction ratio (ARR) was calculated from bilateral BCR waveforms using the worst-side ARR for analysis. Multivariate logistic regression and ROC curve analysis determined independent predictors and optimal thresholds. Stratified 10-fold cross-validation confirmed threshold stability. Results: Patients with short-term or long-term PBD had significantly higher ARRs than those without ( P < 0.001 for both comparisons, Mann-Whitney U test). Furthermore, ARR emerged as the only independent predictor for either short-term (OR 1.287, 95% CI 1.018-1.627, P = 0.035) or long-term PBD (OR 1.153, 95% CI 1.055-1.261, P = 0.002). The threshold values of ARR for predicting short-term and long-term PBD were 59.6% (AUC = 0.991, 95% CI 0.974-1.000, P < 0.001) and 63.6% (AUC = 0.988, 95% CI 0.971-1.000, P < 0.001), respectively. Cross-validation confirmed these thresholds, with mean AUC values of 0.992 and 0.993 for short-term and long-term PBD, respectively. Conclusions: The ARR of the intraoperative BCR waveform showed a high predictive value for PBD in patients with CMCET. We propose a 60% ARR reduction on either side of the BCR waveforms as an exploratory, hypothesis-generating early warning criterion for BCR monitoring during CMCET surgery, pending external validation in independent prospective cohorts before clinical implementation.
- 15 December 2025
- Published by Springer Nature in European Spine Journal
- Vol. 35 (2) , 878-888
Intraoperative shear wave elastography during surgical treatment of intramedullary spinal cord tumors
- 15 December 2025
- Published by Springer Nature in European Spine Journal
- Vol. 35 (2) , 878-888
Intraoperative shear wave elastography during surgical treatment of intramedullary spinal cord tumors
- 15 December 2025
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 144, 111780
Outcomes of initially chosen non-operative management for spinal ependymoma
- 15 December 2025
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 144, 111780
Outcomes of initially chosen non-operative management for spinal ependymoma
- Open Access
- 29 October 2025
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (6) , 1987-2000
Multi-omics analysis delineates molecular signatures of spinal ependymal tumor
Background: Spinal ependymal tumors are a diverse group of neoplasms encompassing four subtypes: spinal ependymoma (SP-EPN), spinal ependymoma, MYCN -amplification (SP-EPN- MYCN ), spinal myxopapillary ependymoma (SP-MPE), and spinal subependymoma (SP-SE). However, the molecular differences among these subtypes remain largely unknown. Methods: Using an integrated multi-omics approach (whole-genome sequencing, RNA-seq, and mass spectrometry), we identified the distinct molecular characteristics of three subtypes except for SP-EPN- MYCN . Results: In SP-EPN, abnormal enrichment of ciliary signaling, particularly involving the MKS complex, was evident. SP-MPE exhibited significant dysregulation of mitochondrial metabolism, reflecting a metabolic profile aligned with the Warburg effect. SP-SE tumors showed enhanced activity of immune-related pathways, including interferon signaling and extracellular vesicle dynamics, suggesting a distinct tumor microenvironment. Conclusion: This pilot study identifies candidate molecular markers in a single-center spinal ependymal tumor cohort. Clinical trial number: Not applicable.
- 29 October 2025
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (6) , 1987-2000
Open AccessMulti-omics analysis delineates molecular signatures of spinal ependymal tumor
Background: Spinal ependymal tumors are a diverse group of neoplasms encompassing four subtypes: spinal ependymoma (SP-EPN), spinal ependymoma, MYCN -amplification (SP-EPN- MYCN ), spinal myxopapillary ependymoma (SP-MPE), and spinal subependymoma (SP-SE). However, the molecular differences among these subtypes remain largely unknown. Methods: Using an integrated multi-omics approach (whole-genome sequencing, RNA-seq, and mass spectrometry), we identified the distinct molecular characteristics of three subtypes except for SP-EPN- MYCN . Results: In SP-EPN, abnormal enrichment of ciliary signaling, particularly involving the MKS complex, was evident. SP-MPE exhibited significant dysregulation of mitochondrial metabolism, reflecting a metabolic profile aligned with the Warburg effect. SP-SE tumors showed enhanced activity of immune-related pathways, including interferon signaling and extracellular vesicle dynamics, suggesting a distinct tumor microenvironment. Conclusion: This pilot study identifies candidate molecular markers in a single-center spinal ependymal tumor cohort. Clinical trial number: Not applicable.
- Open Access
Minimum effective dose of betamethasone for incisional local infiltration for the prevention of postoperative pain after spine surgery: study protocol for a randomised controlled trial
Introduction Postoperative pain is particularly pronounced in spinal surgery. Inadequate management of acute postoperative pain not only reduces patient satisfaction and delays recovery but also increases the risk of developing chronic pain. Local infiltration analgesia (LIA) is a widely used technique for perioperative pain management. However, even with the use of long-acting local anaesthetics, such as ropivacaine, postoperative analgesia often remains insufficient. Preliminary evidence suggests that combining diprospan, a mixture of betamethasone disodium phosphate and betamethasone dipropionate, with ropivacaine can significantly reduce analgesic requirements in the immediate postoperative period. However, concerns about steroid-related complications, including hyperglycaemia and surgical site infections, highlight the need to identify the minimum diprospan concentration to achieve a balance between efficacy and safety. This randomised, controlled, evaluator-blinded trial aims to investigate the dose-response relationship of diprospan as an adjunct to ropivacaine for LIA in spinal surgery to determine the minimum effective dose for effective and safe pain management. Methods and analysis This is a single-centre, randomised, evaluator-blinded, controlled, dose-mapping study in which subjects will be randomised in a 1:1:1:1:1 ratio to the control group or to receive diprospan at concentrations of 0.003%, 0.006%, 0.009% or 0.012%. Patients will receive either 0.5% ropivacaine alone or a corresponding dose of diprospan combined with 0.5% ropivacaine for LIA. All participants will be followed for a duration of 3 months. The primary outcome measure will be cumulative sufentanil consumption within the first 48 hours postsurgery. Secondary outcomes will include additional assessments of analgesia, steroid-related adverse events and other complications within the 3-month follow-up period. Ethics and dissemination This study protocol was approved by the Institutional Review Board of Beijing Tiantan Hospital (KY2024-365-02-1). Written informed consent will be obtained from all participants. The results will be submitted for publication in a peer-reviewed journal. Trial registration number NCT06785350.
Open AccessMinimum effective dose of betamethasone for incisional local infiltration for the prevention of postoperative pain after spine surgery: study protocol for a randomised controlled trial
Introduction Postoperative pain is particularly pronounced in spinal surgery. Inadequate management of acute postoperative pain not only reduces patient satisfaction and delays recovery but also increases the risk of developing chronic pain. Local infiltration analgesia (LIA) is a widely used technique for perioperative pain management. However, even with the use of long-acting local anaesthetics, such as ropivacaine, postoperative analgesia often remains insufficient. Preliminary evidence suggests that combining diprospan, a mixture of betamethasone disodium phosphate and betamethasone dipropionate, with ropivacaine can significantly reduce analgesic requirements in the immediate postoperative period. However, concerns about steroid-related complications, including hyperglycaemia and surgical site infections, highlight the need to identify the minimum diprospan concentration to achieve a balance between efficacy and safety. This randomised, controlled, evaluator-blinded trial aims to investigate the dose-response relationship of diprospan as an adjunct to ropivacaine for LIA in spinal surgery to determine the minimum effective dose for effective and safe pain management. Methods and analysis This is a single-centre, randomised, evaluator-blinded, controlled, dose-mapping study in which subjects will be randomised in a 1:1:1:1:1 ratio to the control group or to receive diprospan at concentrations of 0.003%, 0.006%, 0.009% or 0.012%. Patients will receive either 0.5% ropivacaine alone or a corresponding dose of diprospan combined with 0.5% ropivacaine for LIA. All participants will be followed for a duration of 3 months. The primary outcome measure will be cumulative sufentanil consumption within the first 48 hours postsurgery. Secondary outcomes will include additional assessments of analgesia, steroid-related adverse events and other complications within the 3-month follow-up period. Ethics and dissemination This study protocol was approved by the Institutional Review Board of Beijing Tiantan Hospital (KY2024-365-02-1). Written informed consent will be obtained from all participants. The results will be submitted for publication in a peer-reviewed journal. Trial registration number NCT06785350.
- 2 June 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (4) , 1-8
A Novel Metric for Assessing Long-Term Outcomes in Adults with Chiari Malformation Type I: Occipitocervical Dura Angulation (ODA)—Applications and Value
Foramen magnum decompression with duraplasty (FMDD), a common surgery for adult Chiari malformation type I(CM-I) with a 60–70% improvement rate, lacks assessment metrics. This study applied the concept of occipitocervical dura angulation (ODA) and aimed to investigate ODA’s role in evaluating long-term FMDD outcomes. The ODA normal range was measured in 230 healthy individuals. We included 160 CM-I adults who underwent FMDD over 10 years. Long-term outcomes (> 1 year) were evaluated using the Chicago Chiari Outcome Scale(CCOS). The cohort was grouped to analyze ODA’s role in assessing and predicting FMDD outcomes. The normal range of ODA was 104°-145°, with an average value of 124.2 ± 10.4°. The median patient age was 46 years (range: 18–64 years). The median follow-up period was 64.5 months (range: 18–123 months). The cohort was divided into two groups based on preoperative ODA: group A (n = 90) with ODA < 125° and group B (n = 70) with ODA ≥ 125°. Group B had a significantly better prognosis than that of group A (P = 0.012). Logistic regression analysis revealed that an increase in ODA was associated with clinical outcomes in both groups. The receiver operating characteristic curve showed that ODA increases of > 10° and > 3° could be considered as credible threshold values for groups A and B, respectively. ODA is a reliable predictor of prognosis. FMDD should result in an increased ODA, which is one of the criteria for surgical validity, especially for those with a preoperative ODA of < 125°.
- 2 June 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (4) , 1-8
A Novel Metric for Assessing Long-Term Outcomes in Adults with Chiari Malformation Type I: Occipitocervical Dura Angulation (ODA)—Applications and Value
Foramen magnum decompression with duraplasty (FMDD), a common surgery for adult Chiari malformation type I(CM-I) with a 60–70% improvement rate, lacks assessment metrics. This study applied the concept of occipitocervical dura angulation (ODA) and aimed to investigate ODA’s role in evaluating long-term FMDD outcomes. The ODA normal range was measured in 230 healthy individuals. We included 160 CM-I adults who underwent FMDD over 10 years. Long-term outcomes (> 1 year) were evaluated using the Chicago Chiari Outcome Scale(CCOS). The cohort was grouped to analyze ODA’s role in assessing and predicting FMDD outcomes. The normal range of ODA was 104°-145°, with an average value of 124.2 ± 10.4°. The median patient age was 46 years (range: 18–64 years). The median follow-up period was 64.5 months (range: 18–123 months). The cohort was divided into two groups based on preoperative ODA: group A (n = 90) with ODA < 125° and group B (n = 70) with ODA ≥ 125°. Group B had a significantly better prognosis than that of group A (P = 0.012). Logistic regression analysis revealed that an increase in ODA was associated with clinical outcomes in both groups. The receiver operating characteristic curve showed that ODA increases of > 10° and > 3° could be considered as credible threshold values for groups A and B, respectively. ODA is a reliable predictor of prognosis. FMDD should result in an increased ODA, which is one of the criteria for surgical validity, especially for those with a preoperative ODA of < 125°.
- Open Access
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadu3956
Ara-C suppresses H3 K27–altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity
H3 K27–altered spinal cord diffuse midline glioma (H3-SCDMG) poses therapeutic challenges. Analysis of 73 clinical samples revealed heightened proliferation in H3-SCDMG versus wild-type tumors, suggesting therapeutic vulnerabilities. Drug screening identified cytarabine (Ara-C) as highly effective in inhibiting proliferation in H3 K27M cell models, recently established patient-derived cells, and patient-derived xenograft models. Mechanistically, Ara-C can suppress tumor growth through DNA damage, cell-cycle arrest, and apoptosis. An investigator-initiated clinical trial involving four patients showed benefits in three cases. In addition, a subset of cells exhibited senescence and senescence-associated secretory phenotype post–Ara-C treatment, accompanied by several immune checkpoint ligands’ up-regulation and more immune cell infiltration. Combining Ara-C with dual Programmed cell death protein 1 (PD-1) and TIGIT blockade emerged as a promising strategy to disrupt immune evasion by senescent cells, enhancing antitumor responses. These findings highlight Ara-C’s potential as a monotherapy and in synergy with immunotherapy for H3-SCDMG, offering potential strategies for clinical management.
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadu3956
Open AccessAra-C suppresses H3 K27–altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity
H3 K27–altered spinal cord diffuse midline glioma (H3-SCDMG) poses therapeutic challenges. Analysis of 73 clinical samples revealed heightened proliferation in H3-SCDMG versus wild-type tumors, suggesting therapeutic vulnerabilities. Drug screening identified cytarabine (Ara-C) as highly effective in inhibiting proliferation in H3 K27M cell models, recently established patient-derived cells, and patient-derived xenograft models. Mechanistically, Ara-C can suppress tumor growth through DNA damage, cell-cycle arrest, and apoptosis. An investigator-initiated clinical trial involving four patients showed benefits in three cases. In addition, a subset of cells exhibited senescence and senescence-associated secretory phenotype post–Ara-C treatment, accompanied by several immune checkpoint ligands’ up-regulation and more immune cell infiltration. Combining Ara-C with dual Programmed cell death protein 1 (PD-1) and TIGIT blockade emerged as a promising strategy to disrupt immune evasion by senescent cells, enhancing antitumor responses. These findings highlight Ara-C’s potential as a monotherapy and in synergy with immunotherapy for H3-SCDMG, offering potential strategies for clinical management.
- 11 February 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 172 (3) , 675-685
Clinical characteristics and prognostic factors of primary spinal subependymoma: a single-center cohort study and systematic review
Purpose This study analyzed spinal subependymoma (SP-SE) cases to evaluate treatment outcomes and identify factors influencing patient outcomes. Method Clinical data from our institution, along with relevant literature, were reviewed and summarized. Univariate and multivariate logistic regression analyses were conducted to assess factors impacting the prognosis of patients with primary spinal ependymomas. Results Our cohort included 16 males and 11 females, with a mean age of 46.2 ± 12.1 years. Tumors most commonly involved the thoracic spinal cord (37.0%) and an average of 4.8 segments. Approximately half of the tumors exhibited intramedullary to extramedullary growth (48.1%), and the tumors were predominantly eccentric in growth (85.2%). The median symptom duration was 48.0 months (IQR: 18.0–78.0 months), with limb weakness as the most frequent symptom. The median follow-up period was 61.0 months (IQR: 26.0–96.0 months). At the final follow-up, tumor regrowth occurred in 1 patient (3.7%), and 9 patients (33.3%) achieved good neurological outcomes (modified McCormick Scale [MSS] grades I). Multivariate logistic regression analysis revealed that tumors located at the T3-9 vertebral level were associated with worse postoperative neurological function (OR: 0.070, 95% Confidence Interval [CI]: 0.006–0.826, P = 0.035). Additionally, although the difference was not statistically significant, male gender also showed a trend towards an association with worse postoperative neurological function (OR: 0.126, 95% CI: 0.014–1.119, P = 0.063). Conclusion SP-SE generally follows a benign clinical course with favorable long-term survival. However, tumors located at T3-T9 and male patients tend to have worse postoperative neurological outcomes, requiring special attention during treatment.
- 11 February 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 172 (3) , 675-685
Clinical characteristics and prognostic factors of primary spinal subependymoma: a single-center cohort study and systematic review
Purpose This study analyzed spinal subependymoma (SP-SE) cases to evaluate treatment outcomes and identify factors influencing patient outcomes. Method Clinical data from our institution, along with relevant literature, were reviewed and summarized. Univariate and multivariate logistic regression analyses were conducted to assess factors impacting the prognosis of patients with primary spinal ependymomas. Results Our cohort included 16 males and 11 females, with a mean age of 46.2 ± 12.1 years. Tumors most commonly involved the thoracic spinal cord (37.0%) and an average of 4.8 segments. Approximately half of the tumors exhibited intramedullary to extramedullary growth (48.1%), and the tumors were predominantly eccentric in growth (85.2%). The median symptom duration was 48.0 months (IQR: 18.0–78.0 months), with limb weakness as the most frequent symptom. The median follow-up period was 61.0 months (IQR: 26.0–96.0 months). At the final follow-up, tumor regrowth occurred in 1 patient (3.7%), and 9 patients (33.3%) achieved good neurological outcomes (modified McCormick Scale [MSS] grades I). Multivariate logistic regression analysis revealed that tumors located at the T3-9 vertebral level were associated with worse postoperative neurological function (OR: 0.070, 95% Confidence Interval [CI]: 0.006–0.826, P = 0.035). Additionally, although the difference was not statistically significant, male gender also showed a trend towards an association with worse postoperative neurological function (OR: 0.126, 95% CI: 0.014–1.119, P = 0.063). Conclusion SP-SE generally follows a benign clinical course with favorable long-term survival. However, tumors located at T3-T9 and male patients tend to have worse postoperative neurological outcomes, requiring special attention during treatment.